Takeda Pharmaceutical Company Limited recently announced plans to establish Nairobi, Kenya as a regional center of excellence for Sub-Saharan Africa in the area of cancer management – the study and treatment of tumours. The company’s efforts will also include the diagnosis and monitoring of patients with disorders of the blood and bone marrow.
The company is helping to increase access to potentially life-saving medicines for patients with some of the highest unmet medical needs. This approach is focused on countries with less developed and evolving healthcare systems in areas such as Latin America, South East Asia and Africa, where sustainable approaches to tackle barriers that limit access to medicines are needed to make a meaningful impact on patient lives. Of the 38 million people who die from non-communicable diseases each year, three quarters – or 28 million – of these deaths occur in low- and middle-income countries.
The initiative aims to address multiple access barriers common across regions such as Sub-Saharan Africa – including development of AtM-targeted life-cycle management for its existing medicines, accelerated registration of its innovative medicines, increased participation of local centres in clinical trials, establishment of early access programs where applicable, and introduction of innovative approaches to address affordability for those patients whose ability to pay the full cost of treatment is limited.
In countries such as Kenya, Takeda’s approach goes beyond medicines. The company is working with several partners – including governments, NGOs, healthcare professionals, patient associations and local community in multiple Public-Private Partnerships – to enhance local cancer management capacity, increase access to treatment, and address access barriers for other chronic diseases such as diabetes and hypertension.
Takeda has opened a regional office in Nairobi as part of activities to accomplish its goals.